Abbott Xience Stent Int’l Launch Feedback “Positive” As Firm Builds Capacity
This article was originally published in The Gray Sheet
Executive Summary
Abbott is making "steady and significant progress" in expanding manufacturing capacity for its Xience V stent and will be able to meet "optimistic demand expectations" for the device, according to the firm
You may also be interested in...
New Data Is Likely To Add Fuel To The Drug-Eluting-Stent Debate
New trial data presented at the American College of Cardiology annual meeting could be another obstacle to drug-eluting-stent manufacturers' efforts to reverse a year-long sales slump
New Data Is Likely To Add Fuel To The Drug-Eluting-Stent Debate
New trial data presented at the American College of Cardiology annual meeting could be another obstacle to drug-eluting-stent manufacturers' efforts to reverse a year-long sales slump
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up